Entresto Approval History

• FDA approved: Yes (First approved July 7th, 2015)
• Brand name: Entresto
• Generic name: sacubitril and valsartan
• Dosage form: Tablets
• Previous name: LCZ696
• Company: Novartis Pharmaceuticals Corporation
• Treatment for: Heart Failure

Entresto (sacubitril and valsartan) is a neprilysin inhibitor and angiotensin II receptor blocker combination indicated to reduce the risk of death and hospitalization in patients with chronic heart failure.

FDA Approval: The approval of Entresto was based on results from the 8,442-patient PARADIGM-HF study which was stopped early when it was shown Entresto significantly reduced the risk of cardiovascular death and hospitalizations related to heart failure versus ACE-inhibitor enalapril. Analysis of safety data showed that Entresto had a similar tolerability profile to enalapril.

Mechanism: Entresto contains a combination of sacubitril, a first-in-class neprilysin inhibitor, and valsartan, an angiotensin II antagonist already FDA approved as Diovan. It works by reducing the strain on the failing heart.

Administration: Entresto tablets are taken twice daily, usually in conjunction with other heart failure medicines.

Side Effects: Common side effects observed in clinical trial participants being treated with Entresto were low blood pressure (hypotension), high blood potassium levels (hyperkalemia), and poor function of the kidneys (renal impairment).

Additional Information: Angioedema has been reported as a serious side effect of Entresto, and patients are advised to seek emergency medical assistance if they experience symptoms such as trouble breathing.

Development History and FDA Approval Process for Entresto

Date	Article
Jul  7, 2015	FDA Approves Entresto (sacubitril/valsartan) for Heart Failure
Feb 13, 2015	Novartis' Heart Failure Medicine LCZ696 Granted FDA Priority Review
Nov 17, 2014	Nine New Analyses Show Novartis' LCZ696 Could Change Course of Heart Failure for Patients
Aug 30, 2014	Novartis' new heart failure medicine LCZ696 cut cardiovascular deaths by 20% vs. ACE-inhibitor in landmark PARADIGM-HF trial
Aug 27, 2012	New Novartis Phase II data Show LCZ696 May Provide Clinical Benefits in Patients with a Difficult-to-Treat Form of Heart Failure

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.